Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$30.6 million.

  • Dianthus Therapeutics' Cash from Operations fell 4367.33% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.5 million, marking a year-over-year decrease of 7498.16%. This contributed to the annual value of -$78.2 million for FY2024, which is 11209.41% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Operations stood at -$30.6 million for Q3 2025, which was down 4367.33% from -$23.9 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Cash from Operations high stood at $16.4 million for Q3 2022, and its period low was -$30.6 million during Q3 2025.
  • Moreover, its 4-year median value for Cash from Operations was -$14.9 million (2024), whereas its average is -$15.1 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Cash from Operations soared by 7192.78% in 2023 and then crashed by 20708.1% in 2024.
  • Dianthus Therapeutics' Cash from Operations (Quarter) stood at -$8.9 million in 2022, then plummeted by 33.93% to -$11.9 million in 2023, then plummeted by 131.52% to -$27.4 million in 2024, then fell by 11.34% to -$30.6 million in 2025.
  • Its Cash from Operations stands at -$30.6 million for Q3 2025, versus -$23.9 million for Q2 2025 and -$27.6 million for Q1 2025.